GlassScriptPhysician profile
Edward J Weippert
NPI 1992813950
$7,988.07
in general payments reported to CMS, 2019-2025
44 companies · $710 in 2025
The $710 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,565 · 2020: $865 · 2021: $1,573 · 2022: $1,239 · 2023: $906 · 2024: $1,130 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,746.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,407.01 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $856.35 | 2019-2025 | |
| Amgen INC. | $806.73 | 2019-2024 | Evenity, Prolia, Otezla |
| Abbvie INC. | $737.76 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $554.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.91 | 2019-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $321.62 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Janssen Pharmaceuticals, INC | $315.51 | 2019-2022 | |
| Amarin Pharma, INC. | $248.31 | 2019-2022 | |
| Astellas Pharma US INC | $198.94 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $145.45 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $135.42 | 2022 | |
| Sumitomo Pharma America, INC. | $131.75 | 2023-2025 | Gemtesa |
| Grifols USA, LLC | $120.00 | 2024-2025 | Prolastin-C Liquid |
| Medtronic, INC. | $104.98 | 2021-2025 | Intellis Adaptivestim |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Weippert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.